BPG is committed to discovery and dissemination of knowledge
Case Control Study
©Author(s) (or their employer(s)) 2026.
World J Clin Pediatr. Mar 9, 2026; 15(1): 115246
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.115246
Table 1 Socio-demographic, clinical characteristics and scores of children with generalized anxiety disorder and control, n (%)/median (interquartile range)
Parameters
GAD group (n = 25)
Control group (n = 30)
P value
Gender0.128
    Female18 (72)15 (50)
    Male7 (28)15 (50)
Family history of chronic illnesses13 (52.0)21 (65.6)0.298
Family history of psychiatric disorders14 (56)8 (26.7)0.019
Smoking (yes)1 (3.8)0 (0)0.464
COVID-19 history (yes)12 (46.2)12 (40.0)0.64
Parents together (yes)23 (88.5)26 (86.7)0.839
Age (years)160 (135-185)154 (128-177)0.271
BMI percentile45 (22-80)61 (19.1-82)0.622
Time since symptom onset (months)11 (6-25)
RCADS-CV scores
    SAD60 (53-70)44.5 (41-51)< 0.001
    GAD59 (54-68)42 (39-47)< 0.001
    PD68 (52-80)43.5 (39-52)< 0.001
    SP54 (42-72)39 (33-44)< 0.001
    OCD60 (52-69)46.5 (38-51.3)< 0.001
    MDD61 (44-75)42.5 (38-52)< 0.001
    Total65 (51-75)41 (37-47)< 0.001
Table 2 Comparison of biochemical measure levels between the generalized anxiety disorder and control groups, median (interquartile range)

GAD group (n = 25)
Control group (n = 30)
P value1
CRP (mg/L)1.7 (1.2-2.94)1.3 (1.2-1.7)0.034
TNF-α (pg/mL)7.9 (6.4-11.0)9.3 (7.7-11.0)0.466
TWEAK (mg/L)1111 (893-1889)1236 (1009-1380)0.980
IL-6 (pg/mL)2.8 (0.75-3.99)2.8 (0.8-4.0)0.615
IFN-γ (ng/mL)59.4 (38.4-95.4)61.6 (54-84)0.628
Zinc (μg/dL)94 (82-104)100 (93-112)0.073
Neopterin (nmol/L)3.66 (1.84-4.74)2.9 (2.2-3.9)0.674